Cash bar and " some grub" will be available. So even if you're not part of the "twitterverse," join us for some beverages, networking, and a few laughs.
FDA Approvals in 2013: Bad News?
Past performance does not guarantee future results.
Recent headlines note that NME approvals in 2013 are reduced compared to 2012.
Is this decline signaling a continuing decline in our industry? Or is there something else going on?
Our latest blog post discusses this issue, and tries to provide some historical context around the 2013 data.
New Project: Pediculicide for the Indian Market
On-Market Product Ready for Commercialization in India
Lacerta Bio is pleased to represent the opportunity to commercialize a unique product for the treatment of head lice (pediculosis).
Our client's product is a revolutionary solution for the treatment of head lice that is:
Clinically proven
Extraordinarily effective
Completely free of dangerous pesticides
No risk for development of resistance
On the market in a number of countries
Please note that this product is only available for India only. Other markets are unavailable.
Available: OTC / Rx Product Distribution Opportunity
Additional Opportunity to Import Either OTC or Rx Products
Our client is a multinational manufacturer and marketer of finished OTC and Rx products in India.
They currently manufacture and sell branded generic OTC and Rx products in their local markets via a GMP/WHO certified facility.
The OTC products are registered with the FDA (NDC numbers available) and are ready for partnering with companies seeking to access low-cost, high quality products.
Both OTC and Rx products are available for licensing.
Please contact [email protected] for information, or visit the page linked below for a video explanation of the opportunity.
